Nexpoint Asset Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Nexpoint Asset Management’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,544	Closed	-$382K	–	208
2021 Q2	$382K	Buy	1,544 +960	+164%	+$236K	0.08%	110
2021 Q1	$142K	Buy	+584	New	+$143K	0.04%	148

Other funds holding EFTR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Nexpoint Asset Management's EFTR Position: Q3 2021 in Review

Nexpoint Asset Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2021, closing a stake of 1,544 shares — an estimated $382K sold.

Nexpoint Asset Management first reported a position in EFTR in Q1 2021 and held it in 2 quarters. The position peaked at $382K in Q2 2021. 12 funds tracked by Wall St. Rank hold EFTR as of Q3 2021.

Nexpoint Asset Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Nexpoint Asset Management sold 1,544 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $382K.
Nexpoint Asset Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Nexpoint Asset Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $382K in Q2 2021.
12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Nexpoint Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.